Advancing Frontier Therapeutics: SystImmune Doses First Patient in Global Phase III BrenDeLL-Lung01 Trial for Extensive-Stage Small Cell Lung Cancer
Executive Overview In a significant milestone for modern oncology and targeted drug delivery, biopharmaceutical innovator SystImmune has officially dosed the first patient in its global Phase III clinical trial, designated…